Leadership Overview
Versiti has 10 executives leading key functions including strategy, finance, information technology, human resources, and marketing.
Driven by innovation, Versiti is dedicated to improving patient health and enabling healthcare partner success through advanced solutions in transfusion medicine, transplantation, and blood-related diseases, fostering improved outcomes and cost efficiencies nationwide.
Driven by innovation, Versiti is dedicated to improving patient health and enabling healthcare partner success through advanced solutions in transfusion medicine, transplantation, and blood-related diseases, fostering improved outcomes and cost efficiencies nationwide.
Leadership Roles at Versiti
Jacqueline Fredrick - Chief Executive Officer
Jacqueline Fredrick, the Chief Executive Officer at Versiti, directs the organization's overarching strategy and operational execution. Fredrick guides Versiti's mission to enhance patient health and support healthcare partners through innovative blood health solutions. This leadership role involves setting the strategic vision for transfusion medicine, transplantation, and blood-related disease initiatives. Fredrick ensures alignment across all departments to deliver value-added services that improve patient outcomes and create cost efficiencies for healthcare systems. The Chief Executive Officer's focus remains on driving national impact and fostering a culture of continuous improvement within the organization. Jacqueline Fredrick's leadership is central to Versiti's commitment to advancing blood health innovation across the country.
Dennis Mestrich - President & Chief Executive Officer
Dennis Mestrich, the President & Chief Executive Officer at Versiti, spearheads the company's strategic direction and operational management. Mestrich drives Versiti's core mission to improve patient health and empower healthcare partners nationwide through specialized blood health services. This executive position involves overseeing the delivery of innovative solutions in transfusion medicine, transplantation, and the management of blood-related diseases. Mestrich ensures that Versiti's collective efforts translate into tangible benefits, including enhanced patient outcomes, broader access to care, and significant cost efficiencies for healthcare systems. The President & Chief Executive Officer's responsibilities encompass fostering collaboration and ensuring the highest standards of service delivery. Dennis Mestrich's leadership is critical to Versiti's ongoing success and its role as a national leader in blood health innovation.
Christopher Miskel - President & Chief Executive Officer
Christopher Miskel, the President & Chief Executive Officer at Versiti, leads the organization's strategic initiatives and operational framework. Miskel is dedicated to advancing Versiti's mission of improving patient health and supporting healthcare partners through cutting-edge blood health solutions. This executive role involves guiding the development and implementation of services in transfusion medicine, transplantation, and addressing blood-related diseases. Miskel ensures that Versiti's operations contribute to better patient outcomes, increased access to critical care, and greater economic efficiency for healthcare providers across the nation. The President & Chief Executive Officer's purview includes fostering innovation and maintaining Versiti's position as a leader in the field. Christopher Miskel's strategic oversight is fundamental to Versiti's impact on national health.
Byron Buhner - President & Chief Executive Officer
Byron Buhner, the President & Chief Executive Officer at Versiti, directs the company's strategic vision and operational execution. Buhner champions Versiti's mission to enhance patient health and bolster the success of healthcare partners through specialized blood health innovations. This leadership position involves overseeing the provision of value-added solutions in transfusion medicine, transplantation, and the management of blood-related disorders. Buhner ensures that Versiti's integrated approach yields improved patient outcomes, expands healthcare access, and generates cost efficiencies for healthcare systems nationwide. The President & Chief Executive Officer's focus is on driving organizational excellence and advancing the frontiers of blood health science. Byron Buhner's guidance is essential to Versiti's national leadership and its commitment to patient well-being.
Terri Ainsworth - Chief Financial Officer
Terri Ainsworth, the Chief Financial Officer at Versiti, manages the organization's financial health and strategic fiscal planning. Ainsworth oversees all financial operations, ensuring robust resource allocation to support Versiti's mission of improving patient health and enabling healthcare partner success. This role involves developing financial strategies that drive value-added solutions in transfusion medicine, transplantation, and blood-related diseases. The Chief Financial Officer ensures that financial decisions contribute to enhanced patient outcomes, expanded access to care, and cost efficiencies for healthcare systems nationwide. Ainsworth's expertise is critical in maintaining financial stability and supporting Versiti's growth initiatives. Terri Ainsworth's stewardship of financial resources underpins the organization's capacity to innovate and serve its partners effectively.
Anthony Watkins - Executive Vice President & Chief Financial Officer
Anthony Watkins, the Executive Vice President & Chief Financial Officer at Versiti, oversees the organization's financial operations and strategic fiscal planning. Watkins ensures that Versiti's financial resources are optimized to support its mission of advancing patient health and enabling healthcare partner success through innovative blood health solutions. This executive position involves managing financial reporting, budgeting, and investment strategies related to transfusion medicine, transplantation, and blood-related diseases. The Executive Vice President & Chief Financial Officer plays a crucial role in driving financial performance, ensuring cost efficiencies, and supporting the expansion of Versiti's services nationwide. Watkins's financial acumen is vital for Versiti's sustainable growth and its commitment to delivering value. Anthony Watkins's financial leadership strengthens Versiti's capacity to achieve its objectives.
Rodeina Davis - Chief Information Officer
Rodeina Davis, the Chief Information Officer at Versiti, directs the company's technology strategy and digital infrastructure. Davis ensures that Versiti's information systems effectively support the mission to improve patient health and empower healthcare partners through advanced blood health solutions. This executive role involves overseeing the implementation and management of technology critical to transfusion medicine, transplantation, and blood-related disease management. The Chief Information Officer focuses on leveraging technology to enhance operational efficiency, improve data security, and facilitate seamless collaboration across Versiti's national network. Davis's leadership ensures that technological advancements contribute to better patient outcomes and cost efficiencies for healthcare systems. Rodeina Davis's vision for information technology is integral to Versiti's innovative approach.
James Weidner - Executive Vice President & Chief Human Resources Officer
James Weidner, the Executive Vice President & Chief Human Resources Officer at Versiti, leads the organization's human capital strategy and talent management initiatives. Weidner is responsible for cultivating a high-performing workforce that drives Versiti's mission to improve patient health and support its healthcare partners. This role involves developing programs that attract, retain, and develop talent across all levels of the organization, ensuring expertise in transfusion medicine, transplantation, and blood-related diseases. The Executive Vice President & Chief Human Resources Officer ensures that HR policies align with Versiti's commitment to fostering an inclusive and effective work environment. Weidner's focus on people empowers Versiti to deliver exceptional value and achieve its national objectives. James Weidner's leadership in human resources is foundational to Versiti's operational success.
Chrissy Schroeder - Executive Vice President & Chief Marketing Officer
Chrissy Schroeder, the Executive Vice President & Chief Marketing Officer at Versiti, directs the company's marketing and brand strategy. Schroeder is responsible for communicating Versiti's value proposition to healthcare partners and the broader community, reinforcing the mission to improve patient health through blood health innovation. This role involves developing and executing comprehensive marketing campaigns that highlight Versiti's expertise in transfusion medicine, transplantation, and blood-related diseases. The Executive Vice President & Chief Marketing Officer ensures that marketing efforts enhance brand recognition, drive engagement, and support the organization's growth objectives nationwide. Schroeder's strategic vision is key to positioning Versiti as a leader in its field. Chrissy Schroeder's marketing leadership amplifies Versiti's impact and reach.
Lynne Briggs - Vice President & Chief Information Officer
Lynne Briggs, the Vice President & Chief Information Officer at Versiti, leads the organization's information technology infrastructure and digital transformation efforts. Briggs ensures that Versiti's technology systems effectively support the core mission of improving patient health and empowering healthcare partners with advanced blood health solutions. This executive role involves overseeing the development and deployment of technology critical for transfusion medicine, transplantation, and the management of blood-related diseases. The Vice President & Chief Information Officer focuses on enhancing operational efficiency, ensuring data integrity, and driving innovation through technology across Versiti's national operations. Briggs's strategic guidance is essential for maintaining Versiti's competitive edge and delivering superior patient care. Lynne Briggs's commitment to technological excellence supports Versiti's mission.
Explore Leadership Teams in Blood & Organ Banks
CSL is a global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat hemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies.
Company Leadership CR
GN
SL
HS
信达生物制药 specializes in the research, development, and production of innovative biopharmaceuticals. The company focuses on providing advanced therapies for various diseases, particularly in oncology and autoimmune disorders. Its intended clients include healthcare providers, hospitals, and patients seeking effective treatment options. With a commitment to quality and innovation, 信达生物制药 aims to improve patient outcomes through its cutting-edge products.
Company Leadership HX
Founded in 1987 and headquartered in Edison, New Jersey, MTF Biologics is a tissue bank that offers allograft tissue transplant services, orthopedics, wound care, reconstructive surgery, and more.
Company Leadership FE
MK
BA
DA
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Company Leadership HA
MP
KL
SL
Frequently Asked Questions Regarding Versiti Top Executives and Leadership Team
Unlock more people and company data
